[Old and new oral anticoagulants in the management of atrial fibrillation. Hungarian data].
Despite a progress in the management of patients with atrial fibrillation this arrhythmia is one of the major causes of stroke, heart failure, sudden death and cardiovascular morbidity. Oral anticoagulation with vitamin K antagonist or non-vitamin K antagonist markedly reduces stroke and mortality in atrial fibrillation patients. To estimate the real-life vitamin K antagonist and non-vitamin K antagonist oral anticoagulant treatment in past years in Hungary. Analysis of the National Health Insurance Administation database for atrial fibrillation (BNO: I48) between 2010-2015. We assumed that AF patient would turn to health care provides at least once either as inpatients or outpatients in a 5-year period. The patient was accepted as adherent after 6 months therapy and at least 80% oral anticoagulant prescription. The prevalence of AF in Hungary is 3%. The mortality rate of AF 7%-10% per year. The adherence of the old oral anticoagulant treatment was 55%, but it was 69% among patient treated by "new" oral anticoagulant treatment. However, one third of the patients are not treated by effective old or new oral anticoagulant treatment. We need more effort to improve the effective and high adherence oral anticoagulant therapy in our country. Orv Hetil. 2017; 158(39): 1545-1549.